Specialty & Oncology January 2014
Epidermal Growth Factor Receptor Inhibitors and Skin Rash
Cutaneous adverse reactions
have been reported to occur in approximately 90% of patients treated
with an epidermal growth factor receptor inhibitor.
Multiple Myeloma: An Overview of the Disease and Treatment Options
Multiple myeloma is the second most common hematologic malignancy diagnosed in the United States.
Continuing Education
$7.95 Per CE Exam or $69 for 12 Lessons
-
• April 2026 • 2.00 Credits
Managing HIV Coinfections and Complications
-
Pain Management • March 2026 • 2.00 Credits
Updated Guidance for Opioid Use in Pain Management
-
Cardiovascular • February 2026 • 2.00 Credits
Managing Modifiable Risk Factors in Chronic Coronary Disease
Copyright © 2000 - 2024 Jobson Medical Information LLC unless otherwise noted. All rights reserved. Reproduction in whole or in part without permission is prohibited.